REPLY
13.3.2024 14:52:29 CET | Business Wire | Press release
Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2023, which will be submitted for approval to the Shareholders’ Meeting to be held on first call in Turin on 23 April 2024.
The Reply Group closed 2023 with a consolidated turnover of €2,118.0 million, an increase of 12.0% compared to €1.891.1 million in 2022.
All indicators are positive for the period. Consolidated EBITDA was €352.1 million, an increase of 3.5% compared to €340.3 million at December 2022 (growth is 20% net of the COVID funds released in 2022).
EBIT, from January to December, was at €292.7 million, which is an increase of 2.5% compared to €285.5 million at December 2022 (growth is 22.7% net of the COVID funds released in 2022).
The Group net profit was at €186.7 million. In 2022, the corresponding value was €191.0 million.
Following the results achieved in 2023, the Reply Board of Directors decided to propose a dividend distribution of €1 per share to the next Shareholders’ Meeting, which will be payable on 22 May 2024, with the dividend date set on 20 May 2024 (record date 21 May 2024).
As at 31 December 2023, the Group’s net financial position has been positive at €204.9 million (€70.6 million at 31 December 2022). As at 30 September 2023, the net financial position was positive at €189.7 million.
"2023," stated Mario Rizzante, Reply's Chairman, "was the year in which the world became definitively aware that a great new revolution was just around the corner: the advent of artificial intelligence. Reply was able to ride this moment of great discontinuity by closing a growing financial year, but above all by establishing itself among the new leaders in the sector."
"This positioning - continues Mario Rizzante - was possible because Reply, in 2023, was able to capitalise on years of investment made in artificial intelligence, an area where we began operating with our first competence centres as early as 2017. This know-how within the group has allowed us, in a few months, not only to set up dedicated AI units within all the group companies, but above all to specialise more than 20 companies on the introduction of artificial intelligence into the main industrial sectors."
"The future that lies ahead" Mario Rizzante concludes "is still to be written. In a short time, we will be living in a union of automation, artificial intelligence, digital interfaces and connected objects. In front of us there is a great opportunity and at the same time a challenge that, as Reply, we intend to seize and transform into new spaces of growth for our Group."
The manager responsible for preparing the company's financial reports, Dr Giuseppe Veneziano, states in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting entries.
REPLY
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
This press release is a translation, the Italian version will prevail.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313708049/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for futur
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 07:00:00 CET | Press release
SkyDefender is a multi-layer, multi-domain Integrated Air and Missile Defence system providing full protection against all types of air threats, on land, at sea and in space. SkyDefender integrates a network of advanced sensors and effectors with a versatile command and control (C2) system. With its open and modular architecture, it is fully compatible with existing air defence systems. Combining Thales’ expertise in cybersecurity and advanced artificial intelligence through cortAIx, Thales AI accelerator, SkyDefender enables operational superiority and proactive defence against cyberattacks and evolving threats. Thales is capable of delivering this critical protection globally from today. As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 07:00:00 CET | Press release
Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well as speciality care medicines in Japan, including a blockbuster drug. The agreement with Neupharma includes upfront and milestone payments of up to CHF 83.5 million as well as royalties of up to 20% on sales. The population of available patients eligible for corticorelin treatment associated with peritumoral brain edema is estimated at 60,000 in Japan and 500,000 worldwide. Global market potential is forecasted to exceed USD 1 billion annually. Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rig
Galderma Completes Successful Placement of EUR 500 Million Eurobond11.3.2026 06:55:00 CET | Press release
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%. The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction. Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings. Galderma is currently rated ‘BBB’ (stable outlook) by Fitc
Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 202510.3.2026 22:52:00 CET | Press release
- Sustainable Growth Driven by International Expansion - Significant Increase Across Key Metrics Estithmar Holding Q.P.S.C. has announced its financial results for the year ended 31 December 2025. The group reported a 54% increase in revenue to QAR 6.4 billion, compared with QAR 4.2 billion in 2024. Gross profit rose to QAR 2.1 billion, up from QAR 1 billion in 2024, representing growth of 111%. EBITDA reached QAR 1.5 billion, an increase of 102% year-on-year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310410214/en/ Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 2025 (Photo: AETOSWire) Net profit climbed 122% compared with 2024, reaching QAR 938 million. Earnings per share increased by 145% to QAR 0.264. The growth in net profit was primarily driven by higher revenues, particularly from the specialized contracting and healthcare sectors.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
